Treating Self-Abuse in Autism and Mental Retardation

治疗自闭症和智力低下的自虐

• 批准号: 6485783
• 负责人: NEAL G SIMON
• 金额: $ 25万
• 依托单位: AZEVAN PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-01 至 2004-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6485783
• 关键词: Tourette's syndrome; aggression; autism; cell line; chemical structure function; drug design /synthesis /production; drug screening /evaluation; gastrointestinal drug absorption; guinea pigs; impulsive behavior; laboratory mouse; laboratory rat; mental disorder chemotherapy; mental retardation; pharmacokinetics; self destructive behavior; vasopressins; violence

Serenix Pharmaceuticals LLC (SPL) will develop drugs to treat impulsivity, violence and self-injurious behavior in patients with autism, Tourette's syndrome, and mental retardation. These drugs, termed serenics, stop violent behavior without disrupting normal behaviors. No other products are available for these indications. SPL required a series of vasopressin receptor antagonists from Eli Lilly Company that block the vasopression receptor subtype involved in aggression. With Phase I STTR support, SPL chemically modified the original lead series, producing several candidate molecules that exhibit high binding affinity and block biological effects at the target human receptor. The overall objective of Phase II research is to file Investigational New Drug (IND) applications are two promising candidates. To reach this objective, SPL will test two candidates for i) oral absorption and bioavailability, ii) acute and chronic toxicity, and iii) prepare these molecules for GMP grade bulk synthesis and formulation. The completion of the proposed research will provide the data required to meet the chemical and biological criteria established by the FDA for IND applications. PROPOSED COMMERCIAL APPLICATIONS: SPL is focusing on the development of drugs to help in the control of impulsivity, violence, and self-injurious behavior for the management of autism, Tourette'S syndrome, and mental retardation. It is estimated that more than 500,000 patients in the United States alone would have a need for these drugs, with a worldwide market of 1.5 million. These drugs also may be used in the control of violence associated with mania, conduct disorder in a subset of children with ADHD, and Alzheimer's disease. There are no other products on the market for these indications.

Serenix制药有限责任公司（SPL）将开发药物，以治疗冲动，暴力和自我伤害行为的自闭症，图雷特综合征和精神发育迟滞患者。这些药物，被称为serenics，停止暴力行为，而不破坏正常行为。没有其他产品可用于这些适应症。SPL需要一系列来自Eli Lilly公司的血管加压素受体拮抗剂来阻断参与攻击的血管加压素受体亚型。在I期STTR的支持下，SPL对原始先导化合物系列进行了化学修饰，产生了几种候选分子，这些分子表现出高结合亲和力，并阻断了靶向人类受体的生物学效应。第二阶段研究的总体目标是提交研究性新药（IND）申请，这两个申请是有希望的候选药物。为了实现这一目标，SPL将测试两种候选分子的i）口服吸收和生物利用度，ii）急性和慢性毒性，以及iii）制备这些分子用于GMP级散装合成和配制。拟议研究的完成将提供满足FDA为IND申请制定的化学和生物学标准所需的数据。拟议的商业应用：SPL专注于开发药物，以帮助控制冲动，暴力和自我伤害行为，以管理自闭症，妥瑞氏综合症和精神发育迟滞。据估计，仅美国就有50多万患者需要这些药物，全球市场规模为150万。这些药物也可用于控制与躁狂相关的暴力，ADHD儿童的行为障碍和阿尔茨海默病。市场上没有其他产品用于这些适应症。